Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.

about

The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions Population pharmacokinetics and safety of AZD1446, a neuronal nicotinic receptor agonist, administered in healthy volunteers.

P2860

Q34542646-C64B62CA-51FB-48BB-A2C9-52C31CEE583D Q39810642-9281CEF1-0565-48FF-AA2E-B7302C4CD7E8

P2860

Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.

Item

http://www.wikidata.org/entity/Q37952853

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.

@en

Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.

@nl

type

Item

label

Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.

@en

Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.

@nl

prefLabel

Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.

@en

Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.

@nl

P1476

Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.

@en

P2093

Sohita Dhillon

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials.

IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.

Rationale for transdermal drug administration in Alzheimer disease.

Rivastigmine transdermal patch: role in the management of Alzheimer's disease.

Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease.

Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.

Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease.

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.

Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease.

Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.

P2888

11207090-000000000-00000

P304

927-930

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11207090-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1010146168

http://www.w3.org/2001/XMLSchema#string

P698

22054233

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

rivastigmine

dementia

Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.

about

P2860

P2860

Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921